CD79B and non-Hodgkin lymphoma: This study aimed to evaluate the effectiveness of polatuzumab vedotin as a CD79B gene-targeting drug for the treatment of Non-Hodgkin Lymphoma (NHL) by adopting a systematic review and meta-analysis research approach.